Skip to main content
. Author manuscript; available in PMC: 2018 Jan 12.
Published in final edited form as: Pediatr Res. 2017 May 31;82(3):527–535. doi: 10.1038/pr.2017.74

Figure 5. Combination therapy of MXD3 siRNA nanocomplexes with doxorubicin, vincristine, cisplatin, and maphosphamide showed additive cytotoxic effects.

Figure 5

SK-N-DZ (a–d) or SK-N-BE (E–H) cells were treated with various drugs as described. (a) Nanocomplexes or doxorubicin only vs. combination (***) p<0.001. (b) Nanocomplexes vs. combination (***) p<0.001. (c) Nanocomplexes or cisplatin only vs. combination (***) p<0.001. (d) Nanocomplexes or maphosphamide vs. combination (***) p<0.001. (e) Nanocomplexes or doxorubicin only vs. combination (***) p<0.001 and (**) p<0.01, respectively. (f) Nanocomplexes only vs. combination (***) p<0.001. Vincristine only vs. combination (***) p<0.001. (g) Nanocomplexes or cisplatin only vs. combination (***) p<0.001. (h) SK-N-BE with MXD3 siRNA nanocomplexes or maphosphamide vs. combination (***) p<0.001.